Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565257 | 1.00 | MAP2K1 (0.59) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL30033668 | 1.00 | MAP2K1 (0.59) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL24350862 | 0.90 | MAP2K1 (0.50) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL20565262 | 0.88 | MAP2K1 (0.57) | MAP2K1MAP2K2 | |
| SCHEMBL30034530 | 0.88 | MAP2K1 (0.57) | MAP2K1MAP2K2 | |
| SCHEMBL4131897 | 0.87 | MAP2K1 (0.55) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL22045797 | 0.87 | MAP2K1 (0.60) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL22045796 | 0.87 | MAP2K1 (0.60) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL22045817 | 0.86 | MAP2K1 (0.59) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL22045845 | 0.86 | MAP2K1 (0.57) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3624795-B1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS INC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2021-12-09 | — | — | US | disclosed |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (MA) | 2021-04-27 | — | — | US | disclosed |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| EP-3624795-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFlection Therapeutics, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213807-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885BRAF 2596/4885 |
| US-20210380601-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885BRAF 3/4885 |
| US-20220087989-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NCOA3, TYR, CYP3A43 | MAP2K1 2772/4885MAP2K2 2465/4885BRAF 152/4885 |
| US-10988483-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 59/4885MAP2K2 34/4885BRAF 3/4885 |
| US-20200172550-A1 | FUSED HETEROAROMATIC-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, CYP19A1, BRAF | MAP2K1 59/4885MAP2K2 34/4885BRAF 3/4885 |
| US-11542271-B2 | Fused heteroaromatic-aniline compounds for treatment of dermal disorders | TYR, CYP19A1, BRAF | MAP2K1 58/4885MAP2K2 37/4885BRAF 3/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | MAP2K1 3307/4885MAP2K2 3471/4885BRAF 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.